Subsequent Events	6 Months Ended
Jun. 30, 2025
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events August 2025 Private Placement On August 11, 2025, the Company entered into a securities purchase agreement (the “2025 Securities Purchase Agreement”) with certain entities affiliated with Frazier Life Sciences (“Frazier Life Sciences”, and the investing entities collectively, the “Investors”), pursuant to which the Company agreed to issue and sell to the Investors in a private placement (the “2025 Private Placement”) an aggregate of 1.0 million shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share, and pre-funded warrants (the “Pre-Funded Warrants”) to purchase an aggregate of 3.5 million shares of common stock. The purchase price per Share will be $2.24 (or $2.2399 per Pre-Funded Warrant, which represents the purchase price per Share to be sold in the 2025 Private Placement, minus the $0.0001 per share exercise price of each such Pre-Funded Warrant). The Pre-Funded Warrants are exercisable at any time after their original issuance and will not expire until exercised in full. The exercise of the outstanding Pre-Funded Warrants is subject to a beneficial ownership limitation of 9.99%. Following execution of the 2025 Securities Purchase Agreement on August 11, 2025, the Company is entitled to receive the total gross proceeds of $10.0 million, before offering expenses.

Subsequent Events

6 Months Ended

Jun. 30, 2025

August 2025 Private Placement

On August 11, 2025, the Company entered into a securities purchase agreement (the “2025 Securities Purchase Agreement”) with certain entities affiliated with Frazier Life Sciences (“Frazier Life Sciences”, and the investing entities collectively, the “Investors”), pursuant to which the Company agreed to issue and sell to the Investors in a private placement (the “2025 Private Placement”) an aggregate of 1.0 million shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share, and pre-funded warrants (the “Pre-Funded Warrants”) to purchase an aggregate of 3.5 million shares of common stock. The purchase price per Share will be $2.24 (or $2.2399 per Pre-Funded Warrant, which represents the purchase price per Share to be sold in the 2025 Private Placement, minus the $0.0001 per share exercise price of each such Pre-Funded Warrant). The Pre-Funded Warrants are exercisable at any time after their original issuance and will not expire until exercised in full. The exercise of the outstanding Pre-Funded Warrants is subject to a beneficial ownership limitation of 9.99%.

Following execution of the 2025 Securities Purchase Agreement on August 11, 2025, the Company is entitled to receive the total gross proceeds of $10.0 million, before offering expenses.